Shares of BioPharma Credit (LON:BPCR - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 0.91 ($0.01) and last traded at GBX 0.88 ($0.01), with a volume of 3483385 shares changing hands. The stock had previously closed at GBX 0.89 ($0.01).
BioPharma Credit Price Performance
The business's 50 day simple moving average is GBX 0.86 and its 200-day simple moving average is GBX 0.87. The stock has a market capitalization of £1.06 billion, a P/E ratio of 10.12 and a beta of 0.22.
BioPharma Credit Cuts Dividend
The company also recently declared a dividend, which was paid on Thursday, March 13th. Stockholders of record on Thursday, February 6th were given a dividend of $0.03 per share. The ex-dividend date of this dividend was Thursday, February 6th. This represents a dividend yield of 3.4%. BioPharma Credit's dividend payout ratio is 7,957.15%.
About BioPharma Credit
(
Get Free Report)
BioPharma Credit PLC, an investment trust, primarily invests in interest-bearing debt assets. Its debt assets are secured by royalties or other cash flows derived from the sales of approved life sciences products. The company was incorporated in 2016 and is based in London, the United Kingdom.
Featured Articles
Before you consider BioPharma Credit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioPharma Credit wasn't on the list.
While BioPharma Credit currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.